LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS

Objectives. Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) represents a gold standard option for the treatment of advanced PD and the benefits of intestinal gel delivery are significative superior from those obtained with available medical therapies. We aimed to investigate...

Full description

Bibliographic Details
Main Authors: Luminita Celia POPA, Daniel-Corneliu LEUCUTA, Nicoleta TOHANEAN, Stefan-Lucian POPA, Lacramioara PERJU-DUMBRAVA
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2020-06-01
Series:Romanian Journal of Neurology
Subjects:
pd
Online Access:https://rjn.com.ro/articles/2020.2/RJN_2020_2_Art-05.pdf
id doaj-a978a4f21a8b4da096c945c30b46e9a7
record_format Article
spelling doaj-a978a4f21a8b4da096c945c30b46e9a72021-07-21T09:36:51ZengAmaltea Medical Publishing HouseRomanian Journal of Neurology1843-81482069-60942020-06-01122848810.37897/RJN.2020.2.5LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONSLuminita Celia POPA 0Daniel-Corneliu LEUCUTA1Nicoleta TOHANEAN 2Stefan-Lucian POPA3Lacramioara PERJU-DUMBRAVA4Neurology Department, „Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaDepartment of Medical Informatics and Biostatistics "Iuliu Hatieganu“ University of Medicine and Pharmacy, Cluj-Napoca, Romania Neurology Department, „Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania2nd Medical Department, „Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca, RomaniaNeurology Department, „Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, RomaniaObjectives. Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) represents a gold standard option for the treatment of advanced PD and the benefits of intestinal gel delivery are significative superior from those obtained with available medical therapies. We aimed to investigate the percutaneous endoscopic transgastric jejunostomy (PEG-J) use and the occurrence of procedural complications in a group of patients diagnosed with PD Hoehn and Jahr 3 and 4 stages, receiving LCIG therapy. Materials and methods. We performed an observational retrospective cohort study on 24 PD patients recruited from a single regional tertiary center in Cluj-Napoca, Romania, between 2009 and 2019. We included PD patients with Hoehn and Jahr 3 and 4 stages under LCIG therapy.results. PEG-J replacement was found in 54.2% of the patients. Erythema and inflammation at the level of stoma (37.5%) and allergic reactions (20.8%) were the most common complications. The most frequent reason for PEG-J replacement was tube dislocation (20.8%), and rarely the plied tube, the excess of adipose tissue, or bezoar (4.3% each). A third of the patients received PEG-J therapy during the night, after a median time of three years, after PEG-J initiation. A quarter of all the subjects had their Levodopa-Carbidopa therapy interrupted. The median time untill interruption was one year. The reasons for the interruption were patient, or patient’s relative refuses, for a sixth of the cases, or gastric polyps, in very few cases.conclusions. The most frequent complication of LCIG delivered by PEG-J was erythema and inflammation at the level of stoma. However LCIG therapy discontinuation was in particular due to the decision of the patient or relatives.https://rjn.com.ro/articles/2020.2/RJN_2020_2_Art-05.pdfparkinson’s diseasepdgastroenterological complicationslevodopa-carbidopa intestinal gel (lcig)
collection DOAJ
language English
format Article
sources DOAJ
author Luminita Celia POPA
Daniel-Corneliu LEUCUTA
Nicoleta TOHANEAN
Stefan-Lucian POPA
Lacramioara PERJU-DUMBRAVA
spellingShingle Luminita Celia POPA
Daniel-Corneliu LEUCUTA
Nicoleta TOHANEAN
Stefan-Lucian POPA
Lacramioara PERJU-DUMBRAVA
LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
Romanian Journal of Neurology
parkinson’s disease
pd
gastroenterological complications
levodopa-carbidopa intestinal gel (lcig)
author_facet Luminita Celia POPA
Daniel-Corneliu LEUCUTA
Nicoleta TOHANEAN
Stefan-Lucian POPA
Lacramioara PERJU-DUMBRAVA
author_sort Luminita Celia POPA
title LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
title_short LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
title_full LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
title_fullStr LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
title_full_unstemmed LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
title_sort levodopa-carbidopa intestinal gel therapy in parkinson’s disease: procedure complications
publisher Amaltea Medical Publishing House
series Romanian Journal of Neurology
issn 1843-8148
2069-6094
publishDate 2020-06-01
description Objectives. Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) represents a gold standard option for the treatment of advanced PD and the benefits of intestinal gel delivery are significative superior from those obtained with available medical therapies. We aimed to investigate the percutaneous endoscopic transgastric jejunostomy (PEG-J) use and the occurrence of procedural complications in a group of patients diagnosed with PD Hoehn and Jahr 3 and 4 stages, receiving LCIG therapy. Materials and methods. We performed an observational retrospective cohort study on 24 PD patients recruited from a single regional tertiary center in Cluj-Napoca, Romania, between 2009 and 2019. We included PD patients with Hoehn and Jahr 3 and 4 stages under LCIG therapy.results. PEG-J replacement was found in 54.2% of the patients. Erythema and inflammation at the level of stoma (37.5%) and allergic reactions (20.8%) were the most common complications. The most frequent reason for PEG-J replacement was tube dislocation (20.8%), and rarely the plied tube, the excess of adipose tissue, or bezoar (4.3% each). A third of the patients received PEG-J therapy during the night, after a median time of three years, after PEG-J initiation. A quarter of all the subjects had their Levodopa-Carbidopa therapy interrupted. The median time untill interruption was one year. The reasons for the interruption were patient, or patient’s relative refuses, for a sixth of the cases, or gastric polyps, in very few cases.conclusions. The most frequent complication of LCIG delivered by PEG-J was erythema and inflammation at the level of stoma. However LCIG therapy discontinuation was in particular due to the decision of the patient or relatives.
topic parkinson’s disease
pd
gastroenterological complications
levodopa-carbidopa intestinal gel (lcig)
url https://rjn.com.ro/articles/2020.2/RJN_2020_2_Art-05.pdf
work_keys_str_mv AT luminitaceliapopa levodopacarbidopaintestinalgeltherapyinparkinsonsdiseaseprocedurecomplications
AT danielcorneliuleucuta levodopacarbidopaintestinalgeltherapyinparkinsonsdiseaseprocedurecomplications
AT nicoletatohanean levodopacarbidopaintestinalgeltherapyinparkinsonsdiseaseprocedurecomplications
AT stefanlucianpopa levodopacarbidopaintestinalgeltherapyinparkinsonsdiseaseprocedurecomplications
AT lacramioaraperjudumbrava levodopacarbidopaintestinalgeltherapyinparkinsonsdiseaseprocedurecomplications
_version_ 1721292878305558528